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Aim. To evaluate maternal TNF-alpha and IL-6 plasma levels in normotensive pregnant women, women with preeclampsia, and
to examine the temporal changes in their levels from theantepartum to the postpartum period correlated with the regression
of preeclampsia. Method. A prospective study was performed in the 2nd Department of Obstetrics and Gynecology, University of
Athens.Bloodsampleswereobtained:(1)antepartumatthetimeofclinicaldiagnosisofthesyndrome,2.12-14weekspostpartum.
Results.NostatisticallysigniﬁcantdiﬀerenceswerefoundinIL-6levels,whereasadiﬀerencewasfoundinTNF-alphalevelsbetween
preeclamptic and controls in antepartum period (0.80 pg/ml versus 0.60 pg/ml, P : .04). Long after delivery, TNF-alpha levels were
signiﬁcantlyhigherinpreeclampticcomparedtonormotensivecontrols(0.86pg/mlversus0.60pg/ml,P : .004).Nodiﬀerencewas
observedinTNF-alphabeforeandafterdeliveryinbothgroups.NodiﬀerencewasnoticedinIL-6levelsinwomenofnormotensive
group long after delivery compared to that before delivery. Long after delivery IL-6 levels were statistically signiﬁcant higher in
preeclamptic women compared to normal controls (3.53 ± 0.52 pg/ml versus 1.69 ± 0.48 pg/ml, P : .02). Conclusion. Preeclamptic
women remain under a status of increased inﬂammatory stress up to 12-14 weeks postpartum despite the fact that all the other
signs of preeclampsia are resolved.
1.Introduction
Although there is no systemic inﬂammation during preg-
nancy, circulating cytokines are found to be elevated in
maternal plasma [1]. More speciﬁcally, normal pregnancy
is characterized by local inﬂammatory response which leads
to local production of proinﬂammatory cytokines that could
be found in the systematic circulation. The presence of such
cytokines in the systematic circulation might secondarily
lead to subclinical systemic inﬂammatory response. In
preeclampsia, a similar but exaggerated response occurs [2].
Preeclampsia is a severe pregnancy-speciﬁc disorder with
an incidence which has been reported to be approximately
5–8% [3]. It is a syndrome deﬁned by hypertension and
proteinuria that also may be associated with myriad other
signs and symptoms and often with subnormal fetal growth
[4, 5]. The mechanisms responsible for the pathogenesis of
preeclampsiahavenotyetbeenclearlyidentiﬁed,butreduced
uterine perfusion and placental ischemia are an important
initiating event in this disorder, and inﬂammatory cytokines
are thought to link placental ischemia with cardiovascular
and renal dysfunction symptoms seen in this disorder [6].
Maternal serum levels of IL-6 and TNF-alpha play a sig-
niﬁcant role in pathogenesis of preeclampsia [7]. TNF-alpha
is produced by monocytes, induces apoptosis, and inhibits
proliferation of trophoblast cells in preeclampsia [8]. The
factthathighercirculatinglevelsofTNF-alphawereobserved
in preeclampsia than in gestational hypertension suggests an
association with disease severity [9]. Moreover, signiﬁcantly
increased soluble TNF-alpha receptors are found in the
plasma of patients with preeclampsia [10]. Soluble TNF-
alpha receptors bind with circulating TNF-alpha leading
to a decrease of the ligand’s availability [10]. At least two
diﬀerent views on the role of soluble receptors of TNF-a in
systemic circulation have been expressed in the literature:
(a) increased levels of TNF-α soluble receptors in systemic
circulation may indicate either increased expression of the
receptors on the cells’ surface, and therefore the increased
sensitivity and responsiveness of these cells to elevated levels
of TNF-a, as it has been shown in the preeclamptic women2 Mediators of Inﬂammation
of our study or increased presence of systemic circulation
proteases of the extracellular part of transmembrane TNF-
α receptor and (b) the presence of TNF-α soluble receptor
in the systemic circulation which does not document their
ability to bind TNF-α in systemic circulation, as the decay of
the proteases is likely to aﬀect the binding capacity. Further-
more,thepoorlyperfusedandhypoxicplacentaisthoughtto
synthesize increased vasoactive factors, for example, soluble
fms-like tyrosine kinase-1, cytokines (TNF-alpha, IL-6),
and angiotensin II type 1 receptor antibodies) [11]. Such
elevations could lead to endothelial dysfunction by decreas-
ing bioavailable nitric oxide and increasing reactive oxygen
species and endothelin-1 which in turn leads to altered renal
function,decreasedrenalpressurenatriuresis,increasedtotal
peripheral resistance, and hypertension [11, 12]. Ischemic
placenta leads to endothelial cell activation/dysfunction
and enhances TNF-alpha synthesis which leads to induced
structural and functional alterations in endothelial cells
leading to preeclampsia via transcriptional regulation of the
endothelin-1 gene by TNF-alpha [13–17].
Conﬂicting results, however, are found regarding the role
of circulating IL-6 and TNF-alpha in a review of the current
literature. Many authors believe that circulating levels of
TNF-alpha and IL-6 are enhanced in preeclamptic patients
comparedwithnormotensiveandnonpregnantwomen[18].
On the contrary, others did not manage to identify a
correlation between maternal serum levels of IL-6 or TNF-
alpha and preeclampsia [19, 20]. Furthermore, there is no
information about maternal blood concentrations of IL-6
and TNF-alpha in women with preeclampsia long time after
delivery.
I nt h ep r e s e n ts t u d y ,w eh a v ee v a l u a t e dm a t e r n a lT N F -
alpha and IL-6 plasma levels in normotensive pregnant
women as well as in women with preeclampsia. We have
alsoexaminedwhetherthetemporalchangesinplasmaTNF-
alphaandIL-6levelsfromtheantepartumtothepostpartum
period correlate with the regression of preeclampsia.
2.MaterialsandMethods
Two groups of patients were studied: normal controls
and women with preeclampsia. The preeclamptic group
consisted of 17 normotensive women who later in their preg-
nancy developed preeclampsia. The diagnosis of preeclamp-
sia was established according to the criteria developed by
the National High Blood Pressure Education Programme
Working Group [21]: systolic blood pressure of more than
140mm Hg, diastolic pressure higher than 90mm Hg on
two diﬀerent occasions after the 20th week of pregnancy and
proteinuria deﬁned as urine secretion of 0.3gr of protein
or higher in a 24-hour urine specimen. Blood pressure was
measured with the blood pressure cuﬀ placed on the left arm
at heart level in sitting position.
All women included in preeclamptic group had severe
preeclampsia because they met one or more of the following
criteria: systolic blood pressure >160mm Hg, diastolic blood
pressure >100mg Hg, proteinuria >2grams in a 24-hour
urinecollection,blurredvision,epigastricorupperquadrant
abdominal pain, vomiting, or subnormal fetal growth.
The control group consisted initially of 19 gestation-age-
matchednormotensivepregnantwomen.Threewomenwere
excluded from the study because one developed gestational
hypertensionandtwogestationaldiabeteslaterinpregnancy.
The rest of the women (16 cases) remained normotensive
and without any complication throughout their pregnancy.
All women had similar socioeconomic status and were
nonsmokers. None was a permanent drug user or had any
known metabolic or renal disease. All women had been
receiving ferrous sulfate supplementation during pregnancy
and had hemoglobin levels of more than 10.5gr/dl.
An informed consent was obtained from all women
participating in the study. The study was approved by the
ethics committee of our institution.
2.1. Procedure Blood Samples. Blood samples were obtained
in two periods: (1) antepartum at the time of clinical
diagnosis of the syndrome and (2) 12–14 weeks postpartum
in normal women as well as in women with preeclampsia
at a time when the harmful eﬀects of preeclampsia were
expected to be absent. Blood samples (15ml) were collected
into citrated vacutainers. The tubes remained for 30minutes
at 4◦C, and the blood samples were centrifuged at 1600g for
15minutes at a temperature of 4◦C. The supernatant plasma
was separated and stored at −70
◦C.
Enzyme-linkedimmunosorbentassaywasusedforquan-
titative detection of human TNF-alpha, Bender Medsystems
GmbH(BMS223HS),Austria.ThelimitofdetectionofTNF-
alphawasdeterminedtobe0.13pg/ml.Theoverallintraassay
coeﬃcient of variation has been calculated to be 8.5%
while the overall interassay coeﬃcient of variation has been
calculated to be 9.8%. Enzyme-linked immunosorbent assay
was used for quantitative detection of soluble human IL-6,
Bender Medsystems GmbH (BMS213HS), Austria. The limit
of detection of IL-6 was determined to be 0.02pg/ml. The
overall intraassay coeﬃcient of variation has been calculated
tobe6.9%whiletheoverallinterassaycoeﬃcientofvariation
has been calculated to be 8.0%.
2.2. Statistical Analysis. Statistical analysis was performed
with a commercially available statistical package (SPSS v
17.0 Chicago IL). Normality of the pregnancy distribution of
the studied variables was checked by Kolmogorov-Smirnov
test. Student’s t-test or paired t-test was used as appro-
priate for comparison of normally distributed variables,
while nonparametric Wilcoxon rank-sum test was used
for comparison of nonnormally distributed variables, and
values are expressed as mean ± SE for normally distributed
and as median ± 95 conﬁdence intervals for nonnormally
distributed variables. A P level of <.05 was considered
signiﬁcant.
3. Results
Demographic characteristics of the two groups are presented
in Table 1. All women were Caucasian and married. There
were no diﬀerences between the groups regarding maternalMediators of Inﬂammation 3
and gestational age at sampling. The mean systolic and
diastolic blood pressure as well as the neonatal clinical
characteristics is also presented.
Alterations in plasma IL-6 and TNF-alpha levels in
antepartum (A) and postpartum (P) periods are shown in
Table 2.
No statistically signiﬁcant diﬀerences were found in
plasma IL-6 levels between preeclamptic and controls (mean
± SE: 2.66 ± 1.37pg/ml versus 2.44 ± 0.85pg/ml, P :
.9) in antepartum period. On the contrary, a statistically
signiﬁcant diﬀerence was found in TNF-alpha levels in
women with preeclampsia compared to normal pregnant
women(0.80pg/mlrange:0.67–0.92pg/mlversus0.60pg/ml
range: 0.49–3.01pg/ml, P : .04).
Long after delivery, TNF-alpha levels were signiﬁcantly
higher in preeclamptic women (mean ± SE: 0.86pg/ml,
range 0.78–0.94pg/ml) compared to normotensive controls
(mean ± SE: 0.60pg/ml range: 0.50–3.87pg/ml, P : .004).
No diﬀerence was observed in maternal plasma TNF-alpha
before and after delivery in both groups. A drop, but not a
statistically signiﬁcant one, was noticed in plasma IL-6 levels
in women of normotensive group (mean ± SE: 1.69 ±
0.48pg/ml) long after delivery compared to that (mean ±
SE: 2.44 ± 0.85pg/ml P : .4) before delivery.
An increase, but not a statistically signiﬁcant one, was
observed in plasma IL-6 levels of the preeclamptic women
(mean ± SD: 3.53 ± 0.52pg/ml) in postpartum period
compared to that found before delivery (mean ± SD: 2.66
± 1.37pg/ml, P : .3).
As shown in Table 2, long after delivery, IL-6 levels
were statistically signiﬁcantly higher in preeclamptic women
compared to normal controls (mean ± SD: 3.53 ±
0.52pg/ml versus 1.69 ± 0.48pg/ml, P : .02).
4. Discussion
TNF-alphaisapolypeptidecytokineproducedbymonocytes
and macrophages and has a potentially cytotoxic eﬀect
to trophoblasts as demonstrated by in vitro experiments
[22]. TNF-alpha circulates throughout the body responding
to stimuli (infections, agents, or tissue injury) activating
neutrophils, altering the properties of vascular endothelial
cells [23, 24]. It has been shown that it inhibits the
outgrowth of human trophoblast, and the injection of
TNF-alpha into pregnant mice results in the termination
of pregnancy [25]. Elevated TNF-alpha levels may cause
endothelial dysfunction both directly and indirectly. IL-6 is
a multifunctional cytokine that regulates immune responses
and acute phase reactions and may play a central role in host
defence mechanisms [26].
Conﬂicting results are found regarding the role of IL-
6a n dT N F - a l p h ai nar e v i e wo ft h ec u r r e n tl i t e r a t u r e .
Many believe that circulating levels of TNF-alpha and IL-
6 are enhanced in preeclamptic patients compared with
normotensive and nonpregnant women [18]. In two dif-
ferent studies, Page et al. [27] and Tosun et al. [7]h a v e
recently shown that maternal serum levels of IL-6 and TNF-
alpha are signiﬁcantly increased in preeclamptic patients
rising in a way that higher levels are found in patients
with severe compared to mild preeclampsia. Trying to
explain such ﬁndings, Cachovic et al. [28] showed that the
fractional secretion of TNF-alpha is signiﬁcantly reduced in
preeclamptic women, and for this reason they suggest that
the decreased clearance and altered renal excretion of TNF-
alpha may lead to preeclampsia. On the contrary, others
did not manage to identify a correlation between maternal
serumlevelsofIL-6orTNF-alphaandpreeclampsia[19,20].
Furthermore, Montagnana et al. [29] based on their results
concluded that preeclampsia screening based on cytokines
such as IL-6 or TNF-alpha is not proposed.
According to our results, only the circulating levels
of TNF-alpha and not those of IL-6 were enhanced in
women with preeclampsia when compared to normotensive
women. The source of excess TNF-alpha in preeclampsia
remains unclear. The maintenance of elevated TNF-α levels
compared to those of controls, both directly and in the long
period of time after completion of preeclampsia, could lead
to increased stimulation of monocytes and macrophages,
causingoverproductionoffreeradicals:O2andHOCl(based
the oxidative stress theory). Thus, maintaining high TNF-
α levels in systemic circulation may be responsible for
the stimulation or disruption of vascular endothelium in
the distant time after the removal of the causing factor
of preeclampsia which could be expressed by increased
production in the systemic circulation of IL -6. In this
way, the longer-term clinical eﬀects of preeclampsia in
coronary vessels could be justiﬁed, as recent literature argues
that preeclampsia is often followed in the future by coro-
nary heart disease and cardiovascular events. Histological
observations in near term placental bed biopsies, although
still conﬂicting, indicate higher local expression of these
cytokines in preeclamptic patients. Decidual monocytes and
macrophages are also a rich source of TNF-alpha. The
elevated secretion of TNF-alpha by placental villous tissue
in response to hypoxia causes a reduction of endothelial
cell viability and up-regulates the expression of the adhe-
sion molecule E-selectin by the endothelial cell [30]. It
is possible that syncytiotrophoblast could synthesize and
releaseexcessiveamountsofproinﬂammatorycytokinessuch
as TNF-alpha or IL-6 [31] ,b u ta na n a l y s i so fp r o d u c t i o n
from chorionic villous explants failed to show the expected
increase in protein or mRNA for TNF-alpha, IL-6, IL-
1alpha, and IL-1beta in tissue from preeclampsia compared
to that from normal pregnancy [32]. Thus, there is no
convincing evidence that the preeclampsia placenta dissemi-
nates inﬂammatory cytokines into the maternal circulation
[33]. In parallel, in vitro in a dually perfused placental
cotyledon, most of placental TNF-alpha was released to
the maternal side conﬁrming the importance of placentally
produced inﬂammatory mediators in the induction of the
maternal systemic changes [34]. Hypoxia increases TNF-
alpha synthesis by placental villous tissue in vitro [35].
Additionally, chemicals which trigger placental oxidative
stress also stimulate elevated TNF-alpha production by
villous explants [30]. On the other hand, NO hypoxia-
driven changes in IL-6 synthesis by placental explants
were documented. These data contradict the ﬁnding that4 Mediators of Inﬂammation
Table 1: Demographic and clinical characteristics of women with normal pregnancy (NP) and pregnancy complicated by preeclampsia
(PE). There were no diﬀerences between the two groups unless otherwise indicated.
NP:16 PE:17
Maternal age (years) 33.57 ± 4.43 31.14 ± 5.24
Gestational age at sampling (mean ± SD) 34.14 ± 3.63 32.71 ± 3.04
BMI before birth 25 ± 4.04 28.96 ± 6.71
Systolic blood pressure before birth (mean ± SD) 117.6 ± 8.6 175.22 ± 12.7∗
Diastolic blood pressure before birth (mean ± SD) 71.8 ± 7.6 110.7 ± 7.51∗∗
Neonatal weight (gr) 3275.71 ± 333.61 1699.29 ± 625.3∗
Primigravida (N) (%) 10 (62.5) 17 (100)
Admission to the ICU (N) (%) — 5 (31.2)
IUGR neonates (N) (%) — 6 (37.5) ∗
∗P<. 05 versus control.
∗∗P<. 001 versus control.
Table 2: Alterations in maternal plasma TNF-alpha and IL-6 levels in preeclamptic women (PE) and normal control (NP) during the
antepartum (A) and 12–14 weeks postpartum (P).
(A) NP: n:16 PE: n:17 P
IL-6, mean ± SE (pg/ml) 2.44 ± 0.85 2.66 ± 1.37 .9
TNF-alpha, median (95CI) (pg/ml) 0.60 (0.49–3.01) 0.80 (0.67–0.92) .04
(P)IL-6, mean ± SE (pg/ml) 1.69 ± 0.48 3.53 ± 0.52 .02
TNF-alpha, median (95CI) (pg/ml) 0.60 (0.50–3.87) 0.86 (0.78–0.94) .004
preeclampsia is associated with decreased placental IL-6
production [7, 32].
Our results showing no changes of maternal circulating
TNF-alpha and a drop, but not a signiﬁcant one, of IL-
6 levels long after delivery suggest that the source of the
excessive production of TNF-alpha in preeclampsia may be
monocytes, neutrophils, and unlikely placenta itself. This
suggestion is in accordance to that of other authors [36].
The similar concentrations of IL-6 in maternal circula-
tions in both groups in antepartum period may indicate that
the role of circulating IL-6 is limited in the pathogenesis of
preeclampsia and it is opposite to the suggestions of Jirik
et al. [37] that the increased TNF-alpha production aﬀects
the production of IL-6 and its receptor. On the contrary, the
elevatedmaternalconcentrationsofTNF-alphamaybeapart
of the pathogenesis of preeclampsia. Many authors suggest
that elevated circulating TNF-alpha levels may be involved in
the pathogenesis of preeclampsia [14, 38–40].
An interesting ﬁnding of this study is that elevated
circulating TNF-alpha and IL-6 levels were detected long
after delivery in women with preeclampsia. It is well known
that the primary biological activities of proinﬂammatory
cytokines include inﬂammation and endothelial cell activa-
tion [40]. Our ﬁndings suggest that preeclamptic women
remain under a status of increased inﬂammatory stress up
to 12–14 weeks postpartum despite the fact that all the other
signsofpreeclampsiaareresolved.However,aquestioncould
be raised whether increased TNF-alpha levels might be the
consequence rather than the cause of the symptoms.
It is being increasingly recognized that women with a
history of preeclampsia are at an increased risk for devel-
oping cardiovascular diseases [41, 42]. Several mediators
of endothelial cell dysfunction such as oxidative stress,
various inﬂammation factors, and leukocyte adhesion may
contribute to endothelial dysfunction in both preeclampsia
and coronary artery disease [43].
Our study shows that circulating TNF-alpha, but not
IL-6, levels are higher in preeclamptic women—at the time
symptoms are presented—than in healthy pregnant women
in the same period. So we may hypothesize that increased
inﬂammatory factors seen in our material after delivery are
likely to play a role in the pathogenesis of cardiovascular
diseases seen late in life among women with preeclampsia.
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